Jacobio Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Jacobio Pharmaceuticals Co., Ltd., explained in plain language.
-
New pill targets hard-to-treat cancers with rare mutation
Disease control Recruiting nowThis study tests a new drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene called Y220C. The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 144 participants who have already tried at least one other cance…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:07 UTC
-
New drug targets tough cancers with KRAS mutation
Disease control Recruiting nowThis study tests a new drug called JAB-23E73 in adults with advanced solid tumors that have a specific genetic change (KRAS alteration). The goal is to find the safest dose and see if the drug can shrink tumors. About 294 participants will take the drug by mouth, and researchers …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:06 UTC